Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm

October 21st 2024

David C. Fisher, MD, discusses the evolving role of BTK inhibitors in the CLL treatment paradigm.

Markman’s Take: Vibostolimab in dMMR Endometrial Cancer, Adjuvant Chemo in Cervical Cancer, and More

October 21st 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

FDA Accepts NDA Resubmission for First-Line Rivoceranib/Camrelizumab Combo in Unresectable HCC

October 21st 2024

The FDA has accepted the new drug application resubmission for the first-line combination of rivoceranib plus camrelizumab in unresectable HCC.

FDA Approves IDH1/2+ Companion Diagnostic for Vorasidenib in Grade 2 Astrocytoma or Oligodendroglioma

October 21st 2024

The Ion Torrent Oncomine Dx Target Test received regulatory approval as a companion diagnostic to identify patients who are eligible for vorasidenib.

New Global Hematology Journal Strives to Feature Innovative and Adaptable Research

October 21st 2024

Jorge Cortes, MD, inaugural editor-in-chief of Blood Global Hematology, details what type of research the new journal will highlight and its importance.

National Fellows Forum Showcases Next Generation of Lung Cancer Clinicians

October 20th 2024

Oncology fellows with aspirations of entering the lung cancer field gathered in Chicago, Illinois, to share findings from their research, network, and participate in panel discussions featuring expert faculty

Ribociclib Earns Positive CHMP Opinion in HR+/HER2– Early Breast Cancer

October 18th 2024

The CHMP issued a positive opinion recommending the approval of ribociclib plus endocrine therapy in HR+/HER2– early breast cancer at high risk of recurrence.

Selinexor Receives Approval in South Korea for Multiple Myeloma

October 18th 2024

The South Korean Ministry of Food and Drug Safety approved selinexor plus bortezomib and dexamethasone for pretreated patients with multiple myeloma.

Dr Nowakowski on the Significance of the TakeAim Lymphoma Trial in PCNSL

October 17th 2024

Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.

Bel-Sar Elicits Complete Responses in NMIBC

October 17th 2024

Belzupacap sarotalocan produced complete responses in patients with low-grade non–muscle-invasive bladder cancer.

Asciminib Yields Promising Efficacy vs SOC Agents in CML

October 17th 2024

Jorge Cortes, MD, details how asciminib could affect care for patients with CML, diving into key takeaways from the ASC4FIRST trial.

Galinpepimut-S Earns FDA Rare Pediatric Disease Designation for AML

October 16th 2024

The FDA has granted rare pediatric disease designation to galinpepimut-S for acute myeloid leukemia.

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

October 15th 2024

Ian Krop, MD, PhD, and Aditya Bardia, MD, MPH, FASCO, detail how TROP2-directed ADCs have generated excitement in breast cancer and other solid tumors.

Dr Weinberg on the Prognostic Use of ctDNA Testing in Resected CRC

October 14th 2024

Benjamin Adam Weinberg, MD, discusses the ability of ctDNA-based MRD detection to predict the benefit of adjuvant chemotherapy in resected CRC.

Selinexor Paves the Way for More Affordable, Effective Treatment Options in Myelofibrosis

October 14th 2024

Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis.

Tailored Approaches to TKI Dosing Allow for Treatment-Free Remissions and Reduced Toxicity in CML

October 10th 2024

Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.

Exploring Facets of Both the SCLC and NSCLC Therapeutic Landscapes

October 9th 2024

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

ODAC Weighs In on the Future of Perioperative Trial Designs in Resectable NSCLC

October 9th 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail the 11-0 ODAC vote that new trial designs for perioperative regimens in resectable NSCLC should include within-trial assessment of each treatment phase's contribution.

Apalutamide Demonstrates Real-World OS Benefit vs Enzalutamide in mCSPC

October 9th 2024

Apalutamide was associated with an improved 24-month overall survival rate vs enzalutamide in metastatic castration-sensitive prostate cancer.

Phase 3 Study of TAR-200/Cetrelimab Is Discontinued in MIBC

October 8th 2024

The SunRISe-2 trial of TAR-200 plus cetrelimab in muscle-invasive bladder cancer not undergoing radical cystectomy is being discontinued.